Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





Tuberculosis in the United States 2020 Slide Set										Related Pages
					Return to Main Menu
NOTE: The slide set is in the public domain. You may reproduce these slides without permission; however it is requested that you include an attribution that the materials were developed by CDC (e.g., “Source: CDC” or “Slides developed by CDC”). No substantive changes should be made to the content.Tuberculosis (TB) in the United States1993–2020*Slide - 1Tuberculosis (TB) in the United States1993–2020*Slide - 2Tuberculosis (TB) in the United States1993–2020*Slide - 3TB Incidence Rates and Annual Percent Change in Rate, United States, 2010–2020Slide - 4TB-Related Deaths* and Mortality Rates, United States, 1993–2019Slide - 5TB-Related Deaths* and Mortality Rates, United States, 1993–2019Slide - 6Majority of TB Cases Occur in Four States, United States, 2020Slide - 7Top 10 TB Incidence Rates by Metropolitan Statistical Areas (MSAs), United States, 2020Slide - 8TB Incidence Rates* by U.S.-Affiliated Pacific Islands and Hawaii, 2020Slide - 9TB Cases and Incidence Rates by Origin of Birth, United States, 1993–2020Slide - 10TB Incidence Rates by Origin of Birth, United States, 2011–2020Slide - 11TB Incidence Rates* and Percentages by Origin of Birth, United States, 2020 (N=7,145)Slide - 12Top Countries of Birth Among Non-U.S.–born Persons with TB, United States, 2020 (N=5,127)Slide - 13Top Countries of Birth* Among Non-U.S.–born Persons with Highest Percentage of TB, United States, 2020 (N=5,127)Slide - 14Top 10 TB Incidence Rates,* by Country of Birth,† United States, 2016–2020Slide - 15Percentage of TB Cases Among Non-U.S.–born Persons by Years Since Initial Arrival in the United States at Diagnosis, 2020 (N=5,127)Slide - 16Percentage of TB Cases Among Non-U.S.–born Persons by Years Since Initial Arrival in the United States at Diagnosis, 2020 (N=5,127)Slide - 17Percentage of TB Cases Among Non-U.S.–born Persons by Year Since Initial Arrival in the United States at Diagnosis, 2020 (N=5,127)Slide - 18TB Cases by Race/Ethnicity,* United States, 2011–2020Slide - 19TB Cases by Race/Ethnicity,* United States, 2011–2020Slide - 20Percentage of TB Cases by Race/Ethnicity,* United States, 2020 (N=7,174)†Slide - 21Percentage of TB Cases by Race/Ethnicity,* United States, 2020 (N=7,174)†Slide - 22TB Cases Among U.S.-born Persons by Race/Ethnicity,* United States, 2011–2020Slide - 23TB Incidence Rates Among U.S.-born Persons by Race/Ethnicity,* United States, 2011–2020Slide - 24TB Cases Among Non-U.S.–born Persons by Race/Ethnicity,* United States, 2011–2020Slide - 25TB Incidence Rates Among Non-U.S.–born Persons by Race/Ethnicity,* United States, 2011–2020Slide - 26TB Incidence Rates Among Non-U.S.–born and U.S.-born Persons by Race/Ethnicity,* United States, 2011–2020Slide - 27Percentage of TB Cases by Origin and Race/Ethnicity,* United States, 2020†Slide - 28Percentage of TB Cases by Origin and Race/Ethnicity,* United States, 2020†Slide - 29TB Incidence Rates* by Origin and Race/Ethnicity,† United States, 2020Slide - 30TB Cases by Age Group, United States, 1993–2020Slide - 31TB Incidence Rates by Age Group, United States, 1993–2020Slide - 32TB Cases Among U.S.-born Persons by Age Group, United States, 1994–2020Slide - 33TB Incidence Rates* Among U.S.-born Persons by Age Group, United States, 1994–2020Slide - 34TB Cases Among Non-U.S.–born Persons by Age Group, United States, 1994–2020Slide - 35TB Incidence Rates* Among Non-U.S.–born Persons by Age Group, United States, 1994–2020Slide - 36Percentage of TB Cases by Birth Decade, United States, 1993–2020Slide - 37Percentage of TB Cases by Sex and Age Group, United States, 2020Slide - 38Pediatric TB Cases by Age Group, United States, 1993–2020Slide - 39Pediatric TB Cases by Age Group, United States, 1993–2020Slide - 40Percentage of Pediatric TB Cases by Age Group, United States, 2020 (N=317)Slide - 41Pediatric TB Cases by Origin of Birth, United States, 1993–2020Slide - 42Pediatric TB Incidence Rates* by Origin of Birth, United States, 1994–2020Slide - 43Pediatric TB Cases Among U.S.-born Children by Parent/Guardian Status, United States, 2011–2020Slide - 44Percentage of Pediatric TB Cases Among U.S.-born Children by Parent/Guardian Status, United States, 2020 (N=254)Slide - 45TB Cases by Case Verification Criteria, United States, 1993–2020Slide - 46Percentage TB Cases by Case Verification Criteria, United States, 2020 (N=7,174)Slide - 47Percentage of TB Cases by Site of Disease, United States, 2020Slide - 48Percentage of TB Cases* by Initial Drug Regimen, United States, 1993–2020Slide - 49Percentage of TB Cases,* by Initial Drug Regimen, United States, 2020 (N=7,174)Slide - 50Percentage of TB Cases by Mode of Treatment Administration,* United States, 1993–2018†Slide - 51Percentage of TB Cases by Mode of Treatment Administration,* United States, 2018 (N=8,738)Slide - 52Percentage of TB Cases by Completion of TB Therapy, United States, 1993–2018*Slide - 53Percentage of TB Cases by Reason Therapy Stopped, United States, 2018* (N=8,738)Slide - 54TB Cases by Isoniazid Resistance and Origin of Birth, United States, 1993–2020Slide - 55Cases and Percentages of MDR TB by History of TB, United States, 1993–2020Slide - 56Percentage of HIV Coinfection by Age among Persons with TB, United States, 2011–2020Slide - 57Percentage of Selected Risk Factors Among Persons with TB by Origin of Birth, United States, 2020Slide - 58Percentage of Social Risk Factor Among Persons Aged ≥15 Years with TB, United States, 2020Slide - 59Number and Percentage of Correctional Facility* Residents Among Persons Aged ≥15 Years with TB, United States, 1993–2020Slide - 60Five States with the Highest Percentages of TB Cases Diagnosed Among Correctional Facility* Residents Aged ≥15 Years, United States, 2020Slide - 61TB Cases Among Correctional Facility* Residents Aged ≥15 Years by Type of Facility, United States, 1993–2020Slide - 62Percentage of TB Cases Among Persons Aged ≥15 Years, by Primary Occupation, United States, 2020 (N=6,156)Slide - 63Percentage of TB Cases by Status and Cause of Death, United States, 2018* (N=9,006)Slide - 64Percentage of Sputum Culture Conversions Documented, United States, 2018* (N=5,087)Slide - 65National TB Genotyping Surveillance Coverage* United States,† 2004–2020Slide - 66Definitions for TB Genotypingin the United States * MIRU-VNTR=Mycobacterial interspersed repetitive unit–variable number tandem repeat. † The complete set of 24 loci is referred to as 24-locus MIRU-VNTR and is used for U.S. GENType designations.Slide - 67Number of County-based TB Genotype Clusters* by Cluster Size, United States, 2018–2020 * Genotype clusters are defined as two or more cases with matching spoligotype and 24-locus MIRU-VNTR (GENType) within a county during the specified 3-year time period.Slide - 68TB Genotype Clusters by TB GIMS* Alert Levels,† United States, 2018–2020 (N=1,280)Slide - 69Genotyped TB Cases Estimated to be Attributed to Recent Transmission, United States, 2019–2020 (N=12,242)Slide - 70Genotyped Cases Estimated to be Attributed to Limited and Extensive Recent Transmission, United States, 2017–2020Slide - 71Percentages of TB Cases Estimated to be Attributed and Not Attributed to Recent Transmission, by Origin of Birth,* 2019–2020Slide - 72Percentages of TB Cases Estimated to be Attributed and Not Attributed to Recent Transmission, by Origin of Birth,* 2019–2020Slide - 73Percentage of TB Cases Estimated to be Attributed to Extensive Recent Transmission by Race/Ethnicity, United States, 2017–2020Slide - 74Percentage of TB Cases Estimated to be Attributed to Extensive Recent Transmission by Race/Ethnicity, United States, 2017–2020Slide - 75National Tuberculosis Surveillance System Highlights from 2020This slide series was developed as an accompaniment to the document Reported Tuberculosis in the United States, 2020
Download complete set (75 slides) [PPT – 8 MB]
PDF Version [PDF – 1 MB]
Slide Set Narrative [PDF – 342 KB]Related Links
Archived Surveillance Slide Sets
							
					
						Page last reviewed:  October 25, 2021					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue